BioPorto (BIOPOR) - Total Liabilities
Based on the latest financial reports, BioPorto (BIOPOR) has total liabilities worth Dkr32.91 Million DKK (≈ $5.15 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore BioPorto operating cash flow efficiency to assess how effectively this company generates cash.
BioPorto - Total Liabilities Trend (1999–2024)
This chart illustrates how BioPorto's total liabilities have evolved over time, based on quarterly financial data. Check BIOPOR asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
BioPorto Competitors by Total Liabilities
The table below lists competitors of BioPorto ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Prozone Realty Limited
NSE:PROZONER
|
India | Rs7.01 Billion |
|
Bridgemarq Real Estate Services Inc
TO:BRE
|
Canada | CA$247.88 Million |
|
Wanbury Limited
NSE:WANBURY
|
India | Rs3.49 Billion |
|
Media Prima Bhd
KLSE:4502
|
Malaysia | RM721.73 Million |
|
ALT5 Sigma Corporation
NASDAQ:ALTS
|
USA | $83.95 Million |
|
New Delhi Television Limited
NSE:NDTV
|
India | Rs7.78 Billion |
|
Panda Financial Holding Corp Ltd
SHG:600599
|
China | CN¥184.45 Million |
|
Afluente Transmissão de Energia Elétrica S.A
SA:AFLT3
|
Brazil | R$112.60 Million |
Liability Composition Analysis (1999–2024)
This chart breaks down BioPorto's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BIOPOR market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.91 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.94 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.48 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioPorto's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioPorto (1999–2024)
The table below shows the annual total liabilities of BioPorto from 1999 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Dkr28.23 Million ≈ $4.42 Million |
-4.78% |
| 2023-12-31 | Dkr29.65 Million ≈ $4.64 Million |
-22.82% |
| 2022-12-31 | Dkr38.42 Million ≈ $6.01 Million |
+8.86% |
| 2021-12-31 | Dkr35.29 Million ≈ $5.52 Million |
-10.37% |
| 2020-12-31 | Dkr39.37 Million ≈ $6.16 Million |
+126.81% |
| 2019-12-31 | Dkr17.36 Million ≈ $2.72 Million |
+73.53% |
| 2018-12-31 | Dkr10.00 Million ≈ $1.57 Million |
+4.91% |
| 2017-12-31 | Dkr9.54 Million ≈ $1.49 Million |
+50.17% |
| 2016-12-31 | Dkr6.35 Million ≈ $993.50K |
+40.86% |
| 2015-12-31 | Dkr4.51 Million ≈ $705.31K |
-47.29% |
| 2014-12-31 | Dkr8.55 Million ≈ $1.34 Million |
-4.76% |
| 2013-12-31 | Dkr8.98 Million ≈ $1.40 Million |
-53.54% |
| 2012-12-31 | Dkr19.33 Million ≈ $3.02 Million |
+11.65% |
| 2011-12-31 | Dkr17.31 Million ≈ $2.71 Million |
-2.00% |
| 2010-12-31 | Dkr17.66 Million ≈ $2.76 Million |
+267.48% |
| 2009-12-31 | Dkr4.81 Million ≈ $752.09K |
+31.52% |
| 2008-12-31 | Dkr3.65 Million ≈ $571.85K |
-17.79% |
| 2007-12-31 | Dkr4.45 Million ≈ $695.61K |
-80.17% |
| 2006-12-31 | Dkr22.42 Million ≈ $3.51 Million |
+27.96% |
| 2005-12-31 | Dkr17.52 Million ≈ $2.74 Million |
+22.50% |
| 2004-12-31 | Dkr14.30 Million ≈ $2.24 Million |
-0.69% |
| 2003-12-31 | Dkr14.40 Million ≈ $2.25 Million |
+518.60% |
| 2002-12-31 | Dkr2.33 Million ≈ $364.23K |
-41.90% |
| 2001-12-31 | Dkr4.01 Million ≈ $626.92K |
-38.95% |
| 2000-12-31 | Dkr6.56 Million ≈ $1.03 Million |
-52.31% |
| 1999-12-31 | Dkr13.76 Million ≈ $2.15 Million |
-- |
About BioPorto
BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the onset of disease states for management and therapies in Europe, North America, Asia, and internationally. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination of neu… Read more